Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: DaVita (DVA), BridgeBio Pharma (BBIO) and Becton Dickinson (BDX)

Tipranks - Tipranks - Fri Apr 10, 3:48AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on DaVita (DVA), BridgeBio Pharma (BBIO) and Becton Dickinson (BDX).

Easter Sale - 70% Off TipRanks

DaVita (DVA)

Barclays analyst Andrew Mok CFA maintained a Hold rating on DaVita today and set a price target of $158.00. The company’s shares closed last Wednesday at $148.44.

According to TipRanks.com, CFA is a 1-star analyst with an average return of -2.6% and a 45.3% success rate. CFA covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Brookdale Senior Living, and Alignment Healthcare. ;'>

Currently, the analyst consensus on DaVita is a Hold with an average price target of $162.50.

See today’s best-performing stocks on TipRanks >>

BridgeBio Pharma (BBIO)

In a report released today, Eliana Merle from Barclays maintained a Buy rating on BridgeBio Pharma, with a price target of $157.00. The company’s shares closed last Wednesday at $74.14.

According to TipRanks.com, Merle is a 3-star analyst with an average return of 3.1% and a 39.7% success rate. Merle covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Ultragenyx Pharmaceutical, and 4D Molecular Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BridgeBio Pharma with a $101.63 average price target, representing a 37.3% upside. In a report released yesterday, RBC Capital also initiated coverage with a Buy rating on the stock with a $100.00 price target.

Becton Dickinson (BDX)

Barclays analyst Matt Miksic maintained a Buy rating on Becton Dickinson today and set a price target of $202.00. The company’s shares closed last Wednesday at $157.09.

According to TipRanks.com, Miksic is a 4-star analyst with an average return of 2.7% and a 51.5% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., GE Healthcare Technologies Inc, and Bausch + Lomb Corporation. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Becton Dickinson with a $187.70 average price target, which is a 18.8% upside from current levels. In a report issued on March 25, TipRanks – xAI also upgraded the stock to Buy with a $173.00 price target.

Read More on DVA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).